Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) CFO Vineet Agarwal sold 800 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $70.00, for a total transaction of $56,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Vineet Agarwal also recently made the following trade(s):
- On Thursday, October 17th, Vineet Agarwal sold 10,216 shares of Korro Bio stock. The stock was sold at an average price of $78.26, for a total transaction of $799,504.16.
Korro Bio Stock Performance
Korro Bio stock opened at $65.14 on Wednesday. The firm's fifty day moving average price is $49.10 and its 200-day moving average price is $46.85. Korro Bio, Inc. has a fifty-two week low of $30.00 and a fifty-two week high of $98.00.
Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($2.39) by ($0.04). On average, equities analysts forecast that Korro Bio, Inc. will post -10.02 earnings per share for the current year.
Analyst Upgrades and Downgrades
Urgent: This election is rigged
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
A number of equities research analysts recently weighed in on the stock. William Blair began coverage on shares of Korro Bio in a report on Wednesday, August 14th. They issued an "outperform" rating and a $180.00 target price on the stock. Royal Bank of Canada increased their price objective on shares of Korro Bio from $95.00 to $105.00 and gave the company an "outperform" rating in a research note on Monday, October 21st. Raymond James started coverage on shares of Korro Bio in a report on Monday, October 21st. They issued a "strong-buy" rating and a $153.00 price objective for the company. Finally, HC Wainwright raised their price objective on shares of Korro Bio from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Korro Bio currently has an average rating of "Buy" and a consensus price target of $142.17.
Read Our Latest Report on KRRO
Hedge Funds Weigh In On Korro Bio
A number of hedge funds have recently modified their holdings of the company. Quest Partners LLC increased its position in shares of Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company's stock valued at $59,000 after acquiring an additional 1,124 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of Korro Bio by 71.6% during the 2nd quarter. Point72 Asset Management L.P. now owns 456,085 shares of the company's stock valued at $15,448,000 after purchasing an additional 190,259 shares in the last quarter. Driehaus Capital Management LLC bought a new stake in shares of Korro Bio during the 2nd quarter valued at about $3,958,000. Lynx1 Capital Management LP bought a new stake in shares of Korro Bio during the 2nd quarter valued at about $129,000. Finally, Millennium Management LLC boosted its stake in shares of Korro Bio by 38.3% during the 2nd quarter. Millennium Management LLC now owns 84,201 shares of the company's stock valued at $2,852,000 after purchasing an additional 23,307 shares in the last quarter. Hedge funds and other institutional investors own 13.18% of the company's stock.
About Korro Bio
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
